Wire · opportunities
FDA OKs Takeda, Protagonist drug for rare blood cancer
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 31 August 2026 · Fusion42 review
The FDA approved Mimrylo, a drug developed by Takeda and Protagonist for a rare blood cancer, with a broader-than-expected label that opens a potential annual revenue of $2 billion or more for Takeda.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
Your biotech product focus just gained a direct path to US market with a wide label and high revenue potential. This approval signals a key moment to accelerate partnerships and commercial readiness in rare blood cancers.
◆ Coverage
2 sources · 31 Aug 2026
◆ Related on Wire
◆ Topics
BiotechFDA-approvalrare-diseaseblood-cancerbiotechtakedaprotagonist